W warfarin sodium war′-far-in soe′-dee-um (Apo-Warfarin[can], Coumadin, Gen-Warfarin[can], Jantoven, Marevan[aus], Tar-Warfarin[can]) Do not confuse Coumadin with Kemadrin. Category and Schedule Pregnancy Risk Category: D Drug Class: Oral anticoagulant Mechanism of Action A coumarin derivative that interferes with hepatic synthesis of vitamin K–dependent clotting factors, resulting in depletion of coagulation factors II, VII, IX, and X. Therapeutic Effect: Prevents further extension of formed existing clot; prevents new clot formation or secondary thromboembolic complications. Uses Treatment of pulmonary emboli, deep vein thrombosis (DVT), MI, atrial dysrhythmias, to reduce risk of recurrent MI and thromboembolic events. Pharmacokinetics Well absorbed from the GI tract. Metabolized in the liver. Primarily excreted in urine. Not removed by hemodialysis. Half-life: 1.5–2.5 days. Indications and Dosages Anticoagulant PO Adults, Elderly. Initially, 5–15 mg/day for 2–5 days; then adjust based on INR. Maintenance: 2–10 mg/day. Children. Initially, 0.1–0.2 mg/kg (maximum 10 mg). Maintenance: 0.05–0.34 mg/kg/day. Only gold members can continue reading. Log In or Register to continue Share this:Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window) Related Related posts: 4: D 8: H 19: T 23: Z 3: C 17: R Stay updated, free dental videos. Join our Telegram channel Join Tags: Mosbys Dental Drug Reference 11e Jan 5, 2015 | Posted by mrzezo in General Dentistry | Comments Off on 22: W VIDEdental - Online dental courses
W warfarin sodium war′-far-in soe′-dee-um (Apo-Warfarin[can], Coumadin, Gen-Warfarin[can], Jantoven, Marevan[aus], Tar-Warfarin[can]) Do not confuse Coumadin with Kemadrin. Category and Schedule Pregnancy Risk Category: D Drug Class: Oral anticoagulant Mechanism of Action A coumarin derivative that interferes with hepatic synthesis of vitamin K–dependent clotting factors, resulting in depletion of coagulation factors II, VII, IX, and X. Therapeutic Effect: Prevents further extension of formed existing clot; prevents new clot formation or secondary thromboembolic complications. Uses Treatment of pulmonary emboli, deep vein thrombosis (DVT), MI, atrial dysrhythmias, to reduce risk of recurrent MI and thromboembolic events. Pharmacokinetics Well absorbed from the GI tract. Metabolized in the liver. Primarily excreted in urine. Not removed by hemodialysis. Half-life: 1.5–2.5 days. Indications and Dosages Anticoagulant PO Adults, Elderly. Initially, 5–15 mg/day for 2–5 days; then adjust based on INR. Maintenance: 2–10 mg/day. Children. Initially, 0.1–0.2 mg/kg (maximum 10 mg). Maintenance: 0.05–0.34 mg/kg/day. Only gold members can continue reading. Log In or Register to continue Share this:Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window) Related Related posts: 4: D 8: H 19: T 23: Z 3: C 17: R Stay updated, free dental videos. Join our Telegram channel Join
